Carrick Therapeutics, Ltd. has announced that it has raised $60 million in Series C round of funding on December 1, 2022. The transaction included participation from new investor Pfizer Inc. which has invested $35 million and returning investors Arch Venture Partners, L.P., Evotec SE, GV Management Company, LLC, Rosetta Capital VI, LP fund managed by Rosetta Capital Limited, Cambridge Innovation Capital Limited, Lightstone Ventures, L.P., LSV Capital Management, LLC.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.4 USD | +0.55% | -2.31% | -11.77% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
25.4 USD | +0.55% | -2.31% | 143B | ||
9.235 EUR | +0.82% | -30.35% | 1.74B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.77% | 143B | |
+25.83% | 653B | |
+27.00% | 556B | |
-6.76% | 354B | |
+20.34% | 331B | |
+3.00% | 296B | |
+13.09% | 233B | |
+5.46% | 201B | |
-9.61% | 193B | |
-6.26% | 144B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- Carrick Therapeutics, Ltd. announced that it has received $60 million in funding from a group of investors